Next-Generation TKI Therapy for ROS1-Rearranged NSCLC

Next-Generation TKI Therapy for ROS1-Rearranged NSCLC is organized by Global Oncology Academy (GOA).

Publication Dates
Release Date: 03/01/2024
Expiration Date: 03/01/2025

Description:
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

Learning Objectives
After participating in this educational activity, participants should be better able to:

• Discuss current guidelines and standards for molecular testing in real-world practice settings
• Assess the latest evidence of approved ROS1 inhibitors and emerging next-generation TKIs for the treatment of newly diagnosed ROS1-rearranged NSCLC
• Analyze treatment options for patients with ROS1-rearranged, advanced NSCLC in second or subsequent-line therapy focused on acquired resistance mutations and CNS involvement
• Evaluate intracranial penetration and activity against acquired resistance mutations seen with ROS1-targeted TKI therapies
• Evaluate the toxicity profiles of current and emerging ROS1 TKI agents and inform optimal strategies for preventing and mitigating TKI-related adverse events